Navigation Links
Sigma-Aldrich Launches Breakthrough Genome-Editing Tools
Date:9/16/2008

CompoZr(TM) Zinc Finger Nuclease Platform enables Precise, Permanent, and

Heritable Modification of the Genome

ST. LOUIS, Sept. 16 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL) today launched its CompoZr(TM) platform of zinc finger nuclease (ZFN) reagents. The CompoZr ZFN platform of reagents is expected to provide researchers with the ability to target and precisely manipulate the genome of living cells, resulting in cell lines or whole organisms with defined gene deletions, insertions, or corrections. Initially offered as a customized service for developing ZFNs for specific gene targets, the CompoZr ZFN platform will eventually include ZFN-based kits for targeted transgene insertion and a catalog of off-the-shelf reagents for commonly studied gene targets, gene families, and pathways. Applications for Sigma's new platform technology include creation of knockout and knock-in cell lines, cell lines that yield significantly greater amounts of protein, and novel transgenic animal models.

ZFN reagents are a class of engineered DNA-binding proteins that facilitate targeted editing of the genome within a living cell by creating double-strand breaks in DNA at user-specified locations. Double-strand breaks stimulate the cell's natural DNA-repair processes, namely homologous recombination and non-homologous end joining, to induce site-specific mutagenesis. Using CompoZr reagents, researchers can, for the first time, generate precisely targeted genomic edits using a rapid, single-step procedure, resulting in cell lines with permanent and heritable gene deletions, insertions, or modifications. Additionally, Sigma-Aldrich is collaborating with leading academic researchers to demonstrate the effectiveness of ZFNs in the creation of whole animal knockout models in mice and other species, including rats and rabbits.

"Zinc Finger Nuclease technology has held significant promise for more than a decade and is now mature enough to fundamentally alter the way in which research on living cells and organisms is conducted," said Dr. David Smoller, President of Sigma-Aldrich's Research Biotech Business Unit. "By refining ZFN production methods and utilizing our established distribution capabilities, Sigma-Aldrich is making this exciting technology available to life science researchers worldwide."

By facilitating the creation of complete gene knockout and knock-in somatic, embryonic and primary cell lines, ZFNs allow researchers to precisely determine the biological function of a gene in more relevant backgrounds. It is anticipated that ZFN-mediated genome editing could be used to generate novel animal models of disease that more closely mimic human disease, as well as providing more realistic data on the potential toxicity of new drug compounds. For biopharmaceutical manufacturers, ZFNs will enable the creation of cell lines with improved growth characteristics, altered glycosylation properties, and other traits resulting in higher yields.

Through its exclusive partnership with Sangamo BioSciences, Inc. (Nasdaq: SGMO), the pioneer in zinc finger nuclease research, Sigma Life Science is the sole source of validated research reagents incorporating ZFN technology. Sigma Life Science employs high-throughput production methods to create customized ZFN reagents for user-specified gene targets in just six to eight weeks. All CompoZr reagents are functionally validated in a cell line appropriate for the intended organism of interest, and customers are provided with full protocols for use of their reagents and troubleshooting support from Sigma Life Science's experienced technical team.

Sigma-Aldrich has invested over $60 million in its Life Science and High Technology Center in St. Louis, where over 200 scientists work to transform cutting-edge research into first-to-market products that are key to researchers' work in the fields of functional genomics, proteomics and cell biology using its market-leading RNA interference tools, whole genome amplification technology and comprehensive Prestige Antibody(TM) portfolio.

For more information on Sigma-Aldrich's CompoZr zinc finger nuclease technology platform, visit http://www.compozrzfn.com or contact a sales representative at zfn@sial.com.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use our products. Sigma-Aldrich operates in 36 countries and has 8,000 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit our award-winning website at http://www.sigma-aldrich.com.


'/>"/>
SOURCE Sigma-Aldrich
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sigma-Aldrich Signs Exclusive Agreement With IsoSciences, LLC, to Distribute Isotopically Labeled Bioactive Compounds
2. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
3. Sigma-Aldrich (Nasdaq: SIAL) Reports 16.7% Gain in Q2 2008 Diluted EPS. Q2 2008 Sales Rise 14.4%. 2008 Diluted EPS Forecast Raised $.05 to $2.62-$2.72.
4. Sigma-Aldrich Corporations 2nd Quarter 2008 Earnings Conference Call
5. Sangamo BioSciences and Sigma-Aldrich Announce Research and License Agreement With Roche for the Use of ZFN Technology for Generation of Transgenic Animals
6. Sigma-Aldrich Announces Collaboration With Metahelix Life Sciences
7. Sigma-Aldrich Announces Collaboration to Develop Monoclonal Antibodies
8. Sigma-Aldrich Signs Agreement With Plextronics to Distribute Plexcore(R) Organic Electronics Materials
9. Sigma-Aldrich to Present at the Nasdaq 21st Investor Program on Wednesday, May 21, 2008
10. Sigma-Aldrich (Nasdaq: SIAL) CAO & CFO Hogan Plans to Retire; Search for Successor Underway
11. Sigma-Aldrich Recognized by BioInformatics, LLC as Having the Most Useful and Easiest to Use Online and Print Catalogs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2017)... , ... May 15, 2017 , ... ... and development solutions for drugs, biologics and consumer health products, today announced that ... on rare genetic diseases, to support preclinical and clinical development of TA-46, a ...
(Date:5/15/2017)... 15, 2017  IBM (NYSE: IBM ) scientists ... double-stranded DNA molecules with the potential to efficiently ... This technology complements the IBM Research,s "lab-on-a-chip" ... exosomes and which may also contain biomarkers for ... array of diamond shaped micropillars 1 to ...
(Date:5/11/2017)... May 11, 2017   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade cell and tissue hypothermic storage ... "Company"), today reported operational highlights and financial results for the ... product sales reached a new high of $2.4 million in ... the same period in 2016. Revenue growth was driven by ...
(Date:5/11/2017)... ... May 11, 2017 , ... The key to unlocking the cause ... Sclerosis (MS) is a neurological disorder that can rob people of their ability to ... own brain cells. MS arises from a genetic tendency towards the disease combined with ...
Breaking Biology Technology:
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University (PolyU) ... ground breaking 3D fingerprint minutiae recovery and matching technology, pushing contactless ... use in identification, crime investigation, immigration control, security of access and ... ... A research team led by Dr Ajay Kumar ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
Breaking Biology News(10 mins):